Platelet Rich Plasma (PRP) as Terapeutical Option in Erectil Disfunction (DE)

Patients are randomized into 2 groups (A and B), subsequently group A is subjected to a cycle of 6 weekly injections of 3 ml of autologous PRP while group B is subjected to 6 weekly injections of 1 ml of caverject (alprostadil) 20 mcg. After 4 (four) weeks the groups will be crossed, so group A will be subjected to 6 weekly injections of 1 ml of caverject (alprostadil) 20 mcg while group B will be subjected to a cycle of 6 weekly injections of 3 ml of autologous PRP.

NCT Number	NCT06768177
Lead Sponsor	Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Conditions	Erectile Dysfunction Due to General Medical Condition, Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction Associated With Type 2 Diabetes Mellitus, Erectile Dysfunctions
Enrollment	60 participants
Start Date	2023-04-01
Primary Completion	2024-11-01 (estimated)
Study Completion	2025-11-01 (estimated)
Updated on ClinicalTrials.gov	2025-10-02